Document:

Exhibit 10.2

 

RESTRICTED STOCK UNIT AGREEMENT

 

This Restricted Stock Unit Agreement (the “Agreement”) is dated as of                    by and between Axiall Corporation, a Delaware corporation (together with any Subsidiaries, as applicable, the “Company”), and                          (“Grantee” or “You”).

 

1.                                      Grant of Restricted Stock Units.   Subject to and upon the terms, conditions, and restrictions set forth in this Agreement and in the Company’s 2011 Equity and Performance Incentive Plan (the “Plan”), the Company has granted to Grantee, as of                      (the “Date of Grant”),               restricted stock units (otherwise referred to in this Agreement as “Restricted Stock Units”).  Each Restricted Stock Unit shall represent the contingent right to receive one share of Common Stock.

 

2.                                      Restrictions on Transfer of Restricted Stock Units.   The Restricted Stock Units may not be transferred, sold, pledged, exchanged, assigned or otherwise encumbered or disposed of by Grantee.  Any purported transfer, encumbrance or other disposition of the Restricted Stock Units that is in violation of this Agreement shall be null and void, and the other party to any such purported transaction shall not obtain any rights to or interest in the Restricted Stock Units.

 

3.                                      Vesting of Restricted Stock Units.  The Restricted Stock Units specified in Section 1 of this Agreement shall vest as follows:

 

(a)                                 On each of the first three (3) anniversaries of the Date of Grant, a number of Restricted Stock Units equal to thirty-three and one-third percent (33-1/3%) multiplied by the number of Restricted Stock Units specified in Section 1 of this Agreement shall become nonforfeitable on a cumulative basis until 100% of the Restricted Stock Units specified in Section 1 of this Agreement have become nonforfeitable.  Each such anniversary date shall be a settlement date under this Agreement.

 

(b)                                 In the event a Change in Control occurs prior to all of the Restricted Stock Units specified in Section 1 of this Agreement becoming nonforfeitable as provided in Section 3(a) above and while Grantee is an employee of the Company or any Subsidiary, the Restricted Stock Units covered by this Agreement shall become nonforfeitable if, in connection with such Change in Control, the successor corporation does not assume the obligations of the Company under this Agreement or provide Grantee with a substitute award with rights equivalent to the rights provided under this Agreement.

 

Subject to the following sentence, if the obligations of the Company under this Agreement remain unchanged or the successor corporation assumes the obligations of the Company under this Agreement or provides Grantee with a substitute award with rights equivalent to the rights provided under this Agreement, then no such acceleration shall apply and the terms of this Agreement shall apply to the assumed or substitute award, except as may otherwise be provided in a written agreement between Grantee and the Company.

 

Notwithstanding the foregoing, if, following a Change in Control, (i) the obligations of the Company under this Agreement remain unchanged or the successor corporation assumes the obligations of the Company under this Agreement or provides Grantee with a substitute award with rights equivalent to the rights provided under this Agreement and (ii) after the Change in Control, but prior to all of the Restricted Stock Units specified in Section 1 of this Agreement becoming nonforfeitable, the Company or any successor corporation or any subsidiary of either terminates Grantee’s employment without Cause or Grantee terminates his employment for Good Reason, then the Restricted Stock Units covered by this Agreement or any substitute award shall become nonforfeitable upon such termination of employment.

 

 

4.                                      Forfeiture of Restricted Stock Units.  Except as provided in Section 3 or as the Committee may determine on a case-by-case basis, subject to the terms of the Plan, at such time as Grantee ceases to be continuously employed by the Company, any Restricted Stock Units that have not theretofore become nonforfeitable hereunder shall be forfeited.

 

5.                                      Payment of Restricted Stock Units.   To the extent the Restricted Stock Units shall become nonforfeitable pursuant to Section 3(a) above, shares of Common Stock underlying such Restricted Stock Units shall be transferred to Grantee no later than 15 days after the date on which the Restricted Stock Units become nonforfeitable (i.e., the respective settlement date), except as otherwise provided in Section 7.  To the extent the Restricted Stock Units become nonforfeitable pursuant to Section 3(b) above or upon termination of employment following the Change in Control, then even though such Restricted Stock Units become nonforfeitable upon the occurrence of the Change in Control or termination of employment after the Change in Control, payment will not be made to Grantee until the date or dates payment otherwise would have been made in the absence of such Change in Control or termination of employment after the Change in Control had Grantee continued to be employed by the Company.  In such case, shares of Common Stock underlying such Restricted Stock Units shall be transferred to Grantee no later than 15 days after the respective settlement date or dates, except as otherwise provided in Section 7.

 

6.                                      Dividend, Voting and Other Rights.  Grantee shall have no rights of ownership in the shares of Common Stock underlying the Restricted Stock Units and shall have no right to vote such shares of Common Stock until the date on which the shares of Common Stock are transferred to Grantee pursuant hereto.  Dividend equivalents will be paid  in cash on the shares of Common Stock underlying the Restricted Stock Units and shall be deferred (with no earnings accruing) until and paid contingent upon the earning of the related Restricted Stock Units and paid at the same time the underlying shares are transferred to Grantee.

 

7.                                      Retention of Restricted Stock Units by the Company.  The shares of Common Stock underlying the Restricted Stock Units shall be released to Grantee by the Company’s transfer agent at the direction of the Company.  At such time as the Restricted Stock Units become payable as specified in this Agreement, the Company shall direct the transfer agent to forward all such payable shares of Common Stock to Grantee except, in the event that Grantee has notified the Company of his election to satisfy any tax obligations by surrender of a portion of such shares, the transfer agent will be directed to forward the remaining balance of shares after the amount necessary for such taxes has been deducted.

 

8.                                      Restrictive Covenants

 

(a)                                 Confidential Information and Trade Secrets.

 

(i)                                                 Grantee shall hold in a fiduciary capacity for the benefit of the Company all Confidential Information, including but not limited to trade secrets (as “trade secrets” are defined by applicable Georgia law) pursuant to this Agreement and as otherwise required by law.  During Grantee’s employment with the Company and following the termination of Grantee’s employment for any reason, Grantee shall not, without the prior written consent of the Company or as may otherwise be required by law or legal process, use, communicate, or divulge Confidential information to any other person or entity, except that Grantee may disclose Confidential Information to other Company employees and professional advisors of the Company who have a true need to know about such Confidential Information in order to carry out their duties of service to the Company; provided, however, that the non-use and non-disclosure restrictions described herein will only apply for so long as the particular information at issue remains Confidential Information.  The protection afforded to Confidential Information by this Agreement is not intended by the parties hereto to limit, and is intended to be in

 

 

addition to, any protection provided to any such information under any applicable federal, state, or local law.

 

(ii)                                              All files, records, documents, drawings, specifications, data, computer programs, customer or vendor lists, specific customer or vendor information, marketing techniques, business strategies, contract terms, pricing terms, discounts and management compensation of the Company whether prepared by Grantee or otherwise coming into Grantee’s possession, shall remain the exclusive property of the Company and Grantee shall not remove any such items from the premises of the Company, except in furtherance of Grantee’s duties.

 

(iii)                                           It is understood that while employed by the Company, Grantee will promptly disclose to the Company in writing, and assign to the Company Grantee’s interest in any invention, improvement, copyrightable material or discovery made or conceived by Grantee, either alone or jointly with others, which arises out of Grantee’s employment (“Grantee Invention”).  At the Company’s request and expense, Grantee will reasonably assist the Company during the period of Grantee’s employment by the Company and thereafter in connection with any controversy or legal proceeding relating to a Grantee Invention and in obtaining domestic and foreign patent or other protection covering a Grantee Invention.  As a matter of record, Grantee hereby states that he or she has provided below a list of all unpatented inventions in which Grantee owns all or partial interest.  Grantee agrees not to assert any right against the Company with respect to any invention which is not patented or which is not listed.

 

(iv)                                          As requested by the Company and at the Company’s expense, from time to time and upon the termination of Grantee’s employment with the Company for any reason, Grantee will promptly deliver to the Company all copies and embodiments, in whatever form, of all Confidential Information in Grantee’s possession or within his control (including, but not limited to, memoranda, records, notes, plans, photographs, manuals, notebooks, documentation, program listings, flow charts, magnetic media, disks, diskettes, tapes and all other materials containing any Confidential Information) irrespective of the location or form of such material.  If requested by the Company, Grantee will provide the Company with written confirmation that all such materials have been delivered to the Company as provided herein.

 

(b)                                 Non-Solicitation.  During his employment with the Company and for a period of one year following the termination of Grantee’s employment for any reason, Grantee shall not, in any way, directly or indirectly, solicit, divert, or take away or attempt to solicit, divert, or take away (a) any party who is a customer or prospective customer of the Company with which Grantee had Material Contact while employed with the Company, for the purpose of marketing, selling, or providing to any such party any services or products offered by or competitive with the Company’s Business other than general solicitations to the public and not directed specifically at a customer of the Company, or (b) any employee of the Company to terminate such employee’s employment relationship with the Company.

 

(c)                                  Non-Competition.  During Grantee’s employment by the Company and for a period of one year following the termination of Grantee’s employment, Grantee shall not render Services to any person or entity that engages in or owns, invests in, operates, manages, or controls any venture or enterprise which engages or proposes to engage in the Business within the Restricted Territory.  Notwithstanding the foregoing, nothing in this Agreement shall prevent Grantee from owning for passive investment purposes not intended to circumvent this Agreement, less than five percent (5%) of the publicly traded voting securities of any company engaged in the Business (so long as Grantee has no power to manage, operate, advise, consult with or control the competing enterprise and no power, alone or in conjunction with other affiliated parties, to select a director, manager, general partner, or similar governing official of the competing enterprise other than in connection with the normal and customary

 

 

voting powers afforded Grantee in connection with any permissible equity ownership).

 

(d)                                 Remedies: Specific Performance.  The parties acknowledge and agree that Grantee’s breach or threatened breach of any of the restrictions set forth in this Section will result in irreparable and continuing damage to the Company for which there may be no adequate remedy at law and that the Company shall be entitled to equitable relief, including specific performance and injunctive relief as remedies for any such breach or threatened or attempted breach.  Grantee hereby consents to the grant of an injunction (temporary or otherwise) against Grantee or the entry of any other court order against Grantee prohibiting and enjoining him from violating, or directing him to comply with any provision of this Section.  Grantee also agrees that such remedies shall be in addition to any and all remedies, including damages, available to the Company against him for such breaches or threatened or attempted breaches.  In addition, without limiting the remedies of the Company for any breach of any restriction on Grantee set forth in this Section, except as required by law, Grantee shall forfeit any and all Restricted Stock Units set forth in Section 1 hereof if Grantee breaches the covenant applicable to Grantee contained in this Section and the Company will have no obligation to grant or vest any additional Restricted Stock Units.

 

(e)                                  Communication of Contents of Agreement.  During Grantee’s employment and for one year thereafter, Grantee will communicate his obligations under this Section to any person, firm, association, partnership, corporation or other entity which Grantee intends to be employed by, associated with, or represent.

 

(f)                                   Independent Covenants.  The existence of any claim, demand, action or cause of action of Grantee against the Company, whether predicated upon this Agreement or otherwise, is not to constitute a defense to the Company’s enforcement of any of the covenants or agreements contained in this Section.  The Company’s rights under this Agreement are in addition to, and not in lieu of, all other rights the Company may have at law or in equity to protect its confidential information, trade secrets and other proprietary interests.

 

(g)                                  Extension.  If a court of competition jurisdiction finally determines that Grantee has violated any of Grantee’s obligations under this Section, then the period applicable to those obligations is to automatically be extended by a period of time equal in length to the period during which those violations occurred.

 

9.                                      Definitions

 

As used in this Agreement, the following terms shall be defined as follows:

 

(a)                                 “Business” shall mean                                                                         .

 

(b)                                 “Cause” shall mean Grantee shall have committed prior to termination of employment any of the following acts:  (i) an intentional act of fraud, embezzlement, theft, or any other material violation of law in connection with Grantee’s duties or in the course of Grantee’s employment; (ii) intentional wrongful damage to material assets of the Company; (iii) intentional wrongful disclosure of material confidential information of the Company; (iv) intentional wrongful engagement in any competitive activity that would constitute a material breach of the duty of loyalty; or (v) intentional breach of any stated material employment policy of the Company.  Any determination of whether Grantee’s employment was terminated for Cause shall be made by the Committee, whose determination shall be binding and conclusive.

 

(c)                                  “Confidential Information” shall mean “trade secrets,” as such term is defined by

 

 

applicable Georgia law, and knowledge or data relating to the Company, and  its respective businesses that is not generally known to persons not employed by the Company, is not generally disclosed by the Company and is the subject of reasonable efforts to keep it confidential.  Confidential Information includes, but is not limited to, information regarding:  (i) product or service cost or pricing; (ii)  personnel allocation or organizational structure; (iii)  the business operations or  financial performance of the Company; (iv) sales and marketing plans;  (v) strategic initiatives (independent or collaborative); (vi)  existing or proposed methods of operation; (vii) current and future development and expansion or contraction plans; (viii) sale/acquisition plans; and (ix) non-public information concerning the legal or financial affairs of the Company.  Confidential Information does not include information that has become generally available to the public by the act of one who has the right to disclose such information without violating any right or privilege of the Company.  This definition is not intended to limit any definition of confidential information or any equivalent term under applicable federal, state, or local law.

 

(d)                                 “Good Reason” shall mean: (i) the Company or any Subsidiary reduces Grantee’s total compensation or total compensation potential by a material amount, except to the extent the Company or Subsidiary has instituted a reduction applicable to all senior executives of the Company or (ii) any attempted relocation of Grantee’s place of employment to a location more than 150 miles from the location of such employment on the date of such attempted relocation; provided, that the Grantee’s termination shall only constitute a termination for Good Reason hereunder if (x) the Grantee provides the Company with a notice of termination within 90 days after the initial existence of the facts or circumstances constituting Good Reason; (y) the Company has failed to cure such facts or circumstances within 30 days after receipt of the notice of termination; and (z) the date of termination occurs no later than 120 days after the initial occurrence of the facts or circumstances constituting Good Reason.

 

(e)                                  “Material Contact” shall mean contact between Grantee and any customer or prospective customer (i) with whom Grantee dealt on behalf of the Company; (ii) whose dealings with the Company were coordinated or supervised by Grantee; (iii) about whom Grantee obtained confidential information in the ordinary course of business as a result of Grantee’s association with the Company; or (iv) who receives products authorized by the Company, the sale or provision of which results or resulted in compensation, commissions, or earnings for Grantee.

 

(f)                                   “Restricted Territory” shall mean                                 .  Grantee acknowledges and agrees that the Restricted Territory accurately describes the territory in which the Company manufactures, markets, and/or sells products.

 

(g)                                  “Services” mean services or activities that are the same as or similar to the type provided, conducted, or engaged in by the Grantee within the two year period prior to Grantee’s termination or separation from the Company.

 

10.                               Compliance with Law.  The Company shall make reasonable efforts to comply with all applicable federal and state securities laws; provided, however, notwithstanding any other provision of this Agreement, the Company shall not be obligated to issue any Restricted Stock Units or shares of Common Stock or other securities pursuant to this Agreement if the issuance thereof would, in the reasonable opinion of the Company, result in a violation of any such law.

 

11.                               Relation to Other Benefits.  Any economic or other benefit to Grantee under this Agreement shall not be taken into account in determining any benefits to which Grantee may be entitled.

 

12.                               Amendments.  Any amendment to the Plan shall be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto; provided, however, that no amendment shall adversely affect the rights of Grantee under this Agreement without Grantee’s consent.

 

 

13.                               Severability.  In the event that one or more of the provisions of this Agreement shall be invalidated for any reason by a court of competent jurisdiction, any provision so invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof shall continue to be valid and fully enforceable.

 

14.                               Withholding Taxes.  To the extent that the Company is required to withhold federal, state, local or foreign taxes in connection with any payment made or benefit realized by Grantee under this Agreement, and the amounts available to the Company for such withholding are insufficient, it will be a condition to the receipt of such payment or the realization of such benefit that Grantee make arrangements satisfactory to the Company for payment of the balance of such taxes to be withheld, which arrangements (in the discretion of the Committee) may include relinquishment of a portion of such benefit.  If Grantee fails to make arrangements for the payment of tax, the Company will withhold shares of Common Stock having a value equal to the amount required to be withheld.  Notwithstanding the foregoing, when Grantee is required to pay the Company an amount required to be withheld under applicable income and employment tax laws, Grantee may elect to satisfy the obligation, in whole or in part, by electing to have withheld, from the shares required to be delivered to Grantee, shares of Common Stock having a value equal to the amount required to be withheld.  The shares used for tax withholding will be valued at an amount equal to the Market Value per Share of such shares of Common Stock on the date the benefit is to be included in Grantee’s income.  In no event will the Market Value per Share of the shares of Common Stock to be withheld and delivered pursuant to this Section to satisfy applicable withholding taxes in connection with the benefit exceed the minimum amount of taxes required to be withheld.

 

15.                               Relation to Plan.  This Agreement is subject to the terms and conditions of the Plan.  In the event of any inconsistent provisions between this Agreement and the Plan, the Plan shall govern.  Capitalized terms used herein without definition shall have the meanings assigned to them in the Plan.  The Committee, acting pursuant to the Plan shall, except as expressly provided otherwise herein, have the right to determine any questions which arise in connection with this grant.

 

16.                               Successors and Assigns.  The provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Grantee, and the successors and assigns of the Company.

 

17.                               Governing Law.  The interpretation, performance, and enforcement of this Agreement shall be governed by the laws of the State of Georgia, without giving effect to the principles of conflict of laws thereof.

 

18.                               Consent to Jurisdiction.  Company and Grantee  each (i) hereby irrevocably submits to the exclusive jurisdiction of the federal and state courts located in Atlanta, Georgia for the purpose of any action, claim, cause of action or suit (in contract, tort, or otherwise), inquiry, proceeding or investigation arising out of or based upon this Agreement or relating to the subject matter hereof, (ii) hereby waives to the extent not prohibited by applicable law, and agrees not to assert by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction of the above named courts, that any such proceeding brought in one of the above named courts is improper, or that this Agreement or the subject matter hereof or thereof may not be enforced in or by such court and (iii) hereby agrees not to commence or maintain any action, claim, cause of action, or suit (in contract, tort, or otherwise), inquiry, proceeding, or investigation arising out of or based upon this Agreement or relating to the subject matter hereof or thereof other than before one of the above named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action, claim, cause of action, or suit (in contract, tort, or otherwise), inquiry, proceeding or investigation to any court other than one of the above named courts whether on the grounds of inconvenient forum or

 

 

otherwise.  Company and Grantee  each hereby consents to service of process in any such proceeding in any manner permitted by Georgia law, and agrees that service of process by registered or certified mail, return receipt requested, at the address of Grantee  as reflected in the books and records of the Company  is reasonably calculated to give actual notice.  The provisions of this Section shall not restrict the ability of the Company or Grantee  to enforce in any court any judgment obtained in one of the courts specified in clause (i) of the first sentence of this Section.

 

19.                               Notices.  Any notice to the Company provided for herein shall be in writing to the Company, marked Attention: Vice President, Human Resources, and any notice to Grantee shall be addressed to said Grantee at his address currently on file with the Company.  Except as otherwise provided herein, any written notice shall be deemed to be duly given if and when delivered personally or deposited in the United States mail, first class registered mail, postage and fees prepaid, and addressed as aforesaid.  Any party may change the address to which notices are to be given hereunder by written notice to the other party as herein specified (provided that for this purpose any mailed notice shall be deemed given on the third business day following deposit of the same in the United States mail).

 

20.                               Compliance with Section 409A of the Code.  To the extent applicable, it is intended that this Agreement and the Plan comply with the provisions of Section 409A of the Code, so that the income inclusion provisions of Section 409A(a)(1) do not apply to Grantee.  This Agreement and the Plan shall be administered in a manner consistent with this intent.

 

21.                               Counterparts.  This Agreement may be executed by the parties hereto in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute the same instrument.

 

22.                               Construction.  The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party.  This Agreement will be construed as if drafted jointly by the Company and Executive and no presumption or burden of proof will arise favoring or disfavoring the Company or Executive by virtue of the authorship of any provision in this Agreement. The word “including” in this Agreement means “including without limitation.” All words in this Agreement will be construed to be of such gender or number as the circumstances require.

 

23.                               Data Protection. By signing below, Grantee consents to the Company processing Grantee’s personal data provided herein (the “Data”) exclusively for the purpose of performing this Agreement, in particular in connection with the vesting of Restricted Stock Units awarded herein.  For this purpose the Data may also be disclosed to and processed by companies outside the Company, e.g., banks involved.

 

 

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed on its behalf by its duly authorized officer and Grantee has also executed this Agreement, as of the day and year first above written.

 

	
 
    	
AXIALL    CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    
	
 
    	
Title:
    
	
 
    	
 
    
	
 
    	
 
    
	
GRANTEE:Exhibit 4.2

 

REGISTRATION RIGHTS AGREEMENT

(AMENDED AND RESTATED AS OF [        ], 2013)

 

This Amended and Restated Registration Rights Agreement (this “Agreement”) is made as of [          ], 2013 by and among Acceleron Pharma Inc., a Delaware corporation (the “Corporation”) and the parties listed on Exhibit A hereto (the “Investors”).

 

WHEREAS, the Corporation and the Investors are parties to that certain Amended and Restated Registration Rights Agreement dated as of December 22, 2011 (the “Prior Agreement”).

 

WHEREAS, the Investors executing signature pages hereto hold at least two-thirds in voting power of the outstanding shares of Registerable Shares (as such capitalized term is defined in the Prior Agreement) and therefore may validly join with the Corporation to amend the terms of the Prior Agreement pursuant to Section 19 thereof.

 

WHEREAS, in connection with the initial public offering of the Corporation’s Common Stock, the Investors and the Corporation desire to amend and restate the Prior Agreement as provided herein.

 

NOW, THEREFORE, in consideration of the premises and the mutual agreements hereinafter set forth, the parties hereto agree to amend and restate the Prior Agreement in its entirety as follows:

 

SECTION 1.                            Definitions.  As used in this Agreement, the following terms shall have the following meanings:

 

(a)                                 The term “1934 Act” means the Securities Exchange Act of 1934, as amended.

 

(b)                                 The term “Common Stock” means the Corporation’s Common Stock, $.001 par value per share.

 

(c)                                  The term “Holder” means any holder of Registrable Shares.

 

(d)                                 The terms “register,” “registered,” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and the declaration or ordering of effectiveness of such registration statement.

 

(e)                                  The term “Preferred Stock” means the Corporation’s Series A Convertible Preferred Stock, par value $.001 per share, the Corporation’s Series B Convertible Preferred Stock, par value $.001 per share, the Corporation’s Series C Convertible Preferred Stock, par value $.001 per share, the Corporation’s Series C-1 Convertible Preferred Stock, par value $.001 per share, the Corporation’s Series D Convertible Preferred Stock, par value $.001 per share, the Corporation’s Series D-1 Convertible Preferred Stock, par value $.001 per share, the 

 

1

 

Corporation’s Series E Convertible Preferred Stock, par value $.001 per share, and the Corporation’s Series F Convertible Preferred Stock, par value $.001 per share.

 

(f)                                   The term “Registrable Shares” means (1) the Common Stock issuable upon conversion of Preferred Stock, (2) any Common Stock purchased by an Investor (or its permitted transferees) pursuant to Section 3 of the Amended and Restated Investor Rights Agreement of even date herewith by and among the Corporation and the Investors (or Common Stock issuable with respect to other securities so purchased), (3) for purposes of registrations described in Section 3 of this Agreement only, the Common Stock issuable upon the exercise of warrants issued by the Corporation to RRD International LLC or any affiliate (as defined in Rule 144) of RRD International LLC, (4) for purposes of registrations described in Section 3 of this Agreement only, the Common Stock issuable upon the exercise of warrants issued by the Corporation to General Electric Capital Corporation or any affiliate (as defined in Rule 144) of General Electric Capital Corporation, (5) the Common Stock issuable upon the conversion of the Preferred Stock, or other securities, issuable upon the exercise of warrants issued by the Corporation to Hercules Technology II, L.P. pursuant to the Warrant Agreement dated as of December 21, 2005, (6) the Common Stock issuable upon the exercise of warrants issued by the Corporation to Midcap Funding I, LLC, Silicon Valley Bank and Oxford Finance Corporation or any affiliate (as defined in Rule 144) thereof (collectively, the “Oxford Warrants”), (7) the Common Stock issuable upon the exercise or conversion of Warrants issued by the Corporation to certain of the Investors pursuant to the Series E Stock and Warrant Purchase Agreement dated as of June 10, 2010, and (8) any Common Stock of the Corporation issued as a dividend or other distribution with respect to, or in exchange or in replacement of, such Preferred Stock or Common Stock.  As to any particular Registrable Shares, such shares shall cease to be Registrable Shares when (i) a registration statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been disposed of in accordance with such registration statement, (ii) such securities may be distributed without volume limitation or other restrictions on transfer under Rule 144 or (iii) such securities shall have ceased to be outstanding.

 

(g)                                  The term “Rule 144” means Rule 144 promulgated under the Securities Act.

 

(h)                                 The term “SEC” means the Securities and Exchange Commission.

 

(i)                                     The term “Securities Act” means the Securities Act of 1933, as amended.

 

In addition, for purposes of all calculations and notices under this Agreement, and all other provisions of this Agreement where the context permits, a holder of Preferred Stock shall be deemed the Holder of the Registrable Shares issuable upon conversion thereof, and such Preferred Stock shall be deemed outstanding Registrable Shares hereunder.  Notwithstanding the foregoing, nothing in this Agreement shall require the Corporation actually to register any shares of Preferred Stock.

 

SECTION 2.                            Request for Registration.  If at any time after the earlier to occur of (i) the fourth anniversary of the date of this Agreement and (ii) the date six months after the first public

 

2

 

offering of the Corporation’s securities, the Corporation shall receive a written request (specifying that it is being made pursuant to this Section 2) from a majority of the holders of Registrable Shares (other than the holders of the Oxford Warrants) that the Corporation file a registration statement under the Securities Act, or a similar document pursuant to any other statute then in effect corresponding to the Securities Act, covering the registration of Registrable Shares the expected price to the public of which equals or exceeds $5,000,000 (based on the market price or fair value on the date of such request), then the Corporation shall promptly notify all other Holders (including the holders of the Oxford Warrants) of such request and shall use its best efforts to cause all Registrable Shares that Holders have requested to be registered under the Securities Act on Form S-1 or any other available form the use of which is approved by the Holders of a majority of the Registrable Shares that are to be included in such registration.

 

Notwithstanding the foregoing, (i) the Corporation shall not be obligated to effect a registration pursuant to this Section 2 during the period starting with the date sixty (60) days prior to the Corporation’s estimated date of filing of, and ending on a date six (6) months following the effective date of, a registration statement pertaining to an underwritten public offering of securities for the account of the Corporation; provided, that the Corporation is actively employing in good faith its best efforts to cause such registration statement to become effective and that the Corporation’s estimate of the date of filing such registration statement is made in good faith; (ii) the Corporation shall not be obligated to effect a registration pursuant to this Section 2 within six (6) months after the effective date of a prior registration under this Section 2; and (iii) if the Corporation shall furnish to the Holders a certificate signed by the President of the Corporation stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Corporation or its shareholders for a registration statement to be filed in the near future, then the Corporation’s obligation to use its best efforts to file a registration statement shall be deferred for a period not to exceed 90 days; provided, however, that the Corporation shall not be permitted to so defer its obligation more than once in any 12-month period.

 

The Corporation shall not be obligated to effect more than two registrations on behalf of the Holders pursuant to this Section 2.

 

SECTION 3.                            Corporation Registration.  If at any time the Corporation proposes to register any of its Common Stock under the Securities Act in connection with the public offering of such securities for its own account or for the accounts of shareholders other than Holders, solely for cash on a form that would also permit the registration of the Registrable Shares, the Corporation shall, each such time, promptly give each Holder written notice of such determination.  Upon the written request of any Holder given within twenty (20) days after giving of any such notice by the Corporation, the Corporation shall, subject to the limitations set forth in Section 8, use its best efforts to cause to be registered under the Securities Act all of the Registrable Shares that each such Holder has requested be registered; provided, that the Corporation shall have the right to postpone or withdraw any registration statement relating to an offering in which the Holders are eligible to participate under this Section 3 without any liability or obligation to the Holders under this Section 3.  Further, if all the Investors eligible under this Section 3 to require that their Registrable Shares be included in the registration covering the Corporation’s initial public offering waive their right under this Section 3 with respect to the

 

3

 

Corporation’s initial public offering, then none of RRD International LLC, General Electric Capital Corporation and Hercules Technology II, L.P. shall have any rights under this Sections 3 to require Registerable Shares held by them or their affiliates (as defined in Rule 144) to be included in the Corporation’s initial public offering.

 

SECTION 4.                            Obligations of the Corporation.  Whenever required under Section 2, Section 3 or Section 11 to use its best efforts to effect the registration of any Registrable Shares, the Corporation shall, as expeditiously as reasonably possible:

 

(a)                                 Prepare and file with the SEC a registration statement with respect to such Registrable Shares and use its best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Shares registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such 120-day period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the Corporation; and (ii) in the case of any registration of Registrable Shares on Form S-3 which are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such 120-day period shall be extended for up to 90 days, if necessary, to keep the registration statement effective until all such Registrable Shares are sold.

 

(b)                                 Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement.

 

(c)                                  Furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of such Registrable Shares owned by them.

 

(d)                                 Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably appropriate for the distribution of the securities covered by the registration statement; provided, that the Corporation shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, and further provided that (anything in this Agreement to the contrary notwithstanding with respect to the bearing of expenses) if any jurisdiction in which the securities shall be qualified shall require that expenses incurred in connection with the qualification of the securities in that jurisdiction be borne by selling shareholders, then such expenses shall be payable by selling shareholders pro rata, to the extent required by such jurisdiction.

 

(e)                                  Promptly notify each selling Holder and each underwriter and (if requested by any such person) confirm such notice in writing (A) when a prospectus or any

 

4

 

prospectus supplement or post-effective amendment has been filed and, with respect to a registration statement or any post-effective amendment, when the same has become effective, (B) of the issuance by any state securities or other regulatory authority of any order suspending the qualification or exemption from qualification of any of the Registrable Shares under state securities or Blue Sky laws or the initiation, or threatened initiation, of any proceedings for that purpose, or (C) of the happening of any event which requires the making of any changes in a registration statement or prospectus so that they shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and, as promptly as practicable thereafter, prepare and file with the SEC and furnish a supplement or amendment to such prospectus so that, as thereafter deliverable to the purchasers of such Registrable Shares, such prospectus shall not contain any untrue statement of a material fact or omit a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(f)                                   Notify each selling Holder of Registrable Shares that might reasonably be deemed to be an underwriter or controlling person of the Corporation promptly of any request by the SEC for the amending or supplementing of such registration statement or prospectus or for additional information.

 

(g)                                  Provide a transfer agent for the Common Stock no later than the effective date of the first registration of any Registrable Shares.

 

(h)                                 Otherwise use its best efforts to comply with all applicable rules and regulations of the SEC.

 

(i)                                     Use its best efforts either (i) to cause all such Registrable Shares to be listed on a national securities exchange (if such securities are not already so listed) and on each additional national securities exchange on which similar securities issued by the Corporation are then listed, if the listing of such securities is then permitted under the rules of such exchange, or (ii) to secure designation of all such Registrable Shares as a Nasdaq “national market system security” within the meaning of Rule 11Aa2-1 of the SEC or, failing that, to secure listing on Nasdaq for such Registrable Shares and, without limiting the generality of the foregoing, to arrange for at least two (2) market makers to register as such with respect to Registrable Shares with the Financial Industry Regulatory Authority.

 

(j)                                    Enter into such customary agreements (including an underwriting agreement in customary form) and take such other actions as the selling Holders of Registrable Shares shall reasonably request in order to expedite or facilitate the disposition of such Registrable Shares.

 

(k)                                 Make available for inspection by any selling Holder of Registrable Shares, by any underwriter participating in any disposition to be effected pursuant to such registration statement and by any attorney, accountant or other agent retained by any such selling Holder or any such underwriter, all pertinent financial and other records and pertinent corporate documents and properties of the Corporation, and cause all of the Corporation’s officers, directors and

 

5

 

employees to supply all information reasonably requested by any such selling Holder, underwriter, attorney, accountant or agent in connection with such registration statement.

 

(l)                                     Use every reasonable effort to prevent the issuance of any stop order suspending the effectiveness of such registration statement or of any order preventing or suspending the use of any preliminary prospectus and, if any such order is issued, to obtain the lifting thereof at the earliest reasonable time.

 

(m)                             Make such representations and warranties to the selling Holders of Registrable Shares and the underwriters as are customarily made by issuers to selling stockholders and underwriters, as the case may be, in primary underwritten public offerings.

 

SECTION 5.                            Furnish Information.  It shall be a condition precedent to the obligations of the Corporation to take any action pursuant to this Agreement with respect to the registration of any Holder’s Registrable Shares that such Holder shall take such actions and furnish to the Corporation such information regarding itself, the Registrable Shares held by it, and the intended method of disposition of such securities, as the Corporation shall reasonably request and as shall be required in connection with any registration, qualification or compliance referred to in this agreement, including, without limitation (i) in connection with an underwritten offering, enter into an appropriate underwriting agreement containing terms and provisions then customary in agreements of that nature, (ii) enter into such custody agreements, powers of attorney and related documents at such time and on such terms and conditions as may then be customarily required in connection with such offering and (iii) distribute the Registrable Shares only in accordance with and in the manner of the distribution contemplated by the applicable registration statement and prospectus.  In addition, the Holders shall promptly notify the Corporation of any request by the Commission or any state securities commission or agency for additional information or for such registration statement or prospectus to be amended or supplemented.

 

SECTION 6.                            Expenses of Demand Registration.  All expenses incurred in connection with any registration pursuant to Section 2 or Section 11 (excluding underwriters’ discounts and commissions), including, without limitation, all registration and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Corporation, and the reasonable fees and disbursements of one special counsel for the selling Holders collectively, shall be borne by the Corporation; provided, however, that the Corporation shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Shares to be registered (in which case all participating Holders shall bear such expenses pro rata based upon the number of Registrable Shares that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Shares agree to forfeit their right to one demand registration pursuant to Section 2; provided further, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Corporation from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 2.

 

6

 

SECTION 7.                            Corporation Registration Expenses.  All expenses (excluding underwriters’ discounts and commissions) incurred in connection with any registration pursuant to Section 3, including, without limitation, any additional registration and qualification fees and any additional fees and disbursements of counsel to the Corporation that result from the inclusion of securities held by the selling Holders in such registration and the reasonable fees and disbursements of one special counsel for the selling Holders collectively, shall be borne by the Corporation.

 

SECTION 8.                            Underwriting Requirements.

 

(a)                                 In connection with any offering under Section 3 involving an underwriting of shares being issued by the Corporation, the Corporation shall not be required to include any Holder’s Registrable Shares in such underwriting unless such Holder accepts the terms of the underwriting as agreed upon between the Corporation and the underwriters selected by it, and then only in such quantity as will not, in the reasonable opinion of the underwriters, jeopardize the success of the offering by the Corporation.  If the total amount of securities that all Holders request to be included in an underwritten offering under Section 3 exceeds the amount of securities that the underwriters reasonably believe compatible with the success of the offering, no securities of any shareholder shall be included in such offering, except (i) securities of the shareholder, if any, on whose behalf the registration is undertaken, (ii) securities included in such underwritten offering pursuant to the exercise of contractual demand registration rights and (iii) Registrable Shares of Holders, unless all Registrable Shares which the Holders have requested to be included are included, and the Corporation shall only be required to include in the offering so many of the Registrable Shares of the Holders as the underwriters reasonably believe will not jeopardize the success of the offering (the Registrable Shares so included to be apportioned pro rata among the selling Holders according to the total amount of Registrable Shares owned by such selling Holders, or in such other proportions as shall mutually be agreed to by such selling Holders).

 

(b)                                 With respect to any underwriting of shares to be registered under Section 2 or Section 11, the selling Holders who initiate the request for registration shall have the right to designate the managing underwriter or underwriters, subject to the consent of the Corporation.  In connection with any underwritings of shares to be registered under Section 3, the Corporation shall have the right to designate the managing underwriter or underwriters.  In any such case, such consent of the Corporation or the Holders shall not be unreasonably withheld or delayed.

 

SECTION 9.                            Delay of Registration.  No Holder shall have any right to take any action to restrain, enjoin, or otherwise delay any registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Agreement.

 

SECTION 10.                     Indemnification.  In the event any Registrable Shares are included in a registration statement under this Agreement:

 

(a)                                 To the extent permitted by law, the Corporation will indemnify and hold harmless each Holder requesting or joining in a registration, the partners, members, officers, directors and stockholders of such Holder, legal counsel and accountants for such Holder, any

 

7

 

underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the 1934 Act, against any losses, claims, damages or liabilities, joint or several, to which they may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based on (i) any untrue or alleged untrue statement of any material fact contained in such registration statement, including, without limitation, any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading or (iii) any violation by the Corporation of any rule or regulation promulgated under the Securities Act applicable to the Corporation and relating to action or inaction required of the Corporation in connection with any such registration; and will promptly reimburse each such Holder, underwriter, controlling person or other aforementioned person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Corporation (which consent shall not be unreasonably withheld or delayed) nor shall the Corporation be liable to any such Holder, underwriter, controlling person or other aforementioned person in any such case for any such loss, claim, damage, liability or action to the extent that it (i) arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in connection with such registration statement, preliminary prospectus, final prospectus, or amendments or supplements thereto, in reliance upon and in conformity with written information furnished to the Corporation expressly for use in connection with such registration by or on behalf of such Holder, underwriter, controlling person or other aforementioned person, (ii) is caused by the failure of such Holder to deliver a copy of the final prospectus relating to such Registrable Shares, as then amended or supplemented, in connection with a purchase, if the Corporation had previously furnished copies thereof to such Holder or (iii) is caused by such Holder’s disposition of Registrable Shares during any period during which such Holder is obligated to discontinue any disposition of Registrable Shares under Section 17.

 

(b)                                 To the extent permitted by law, each Holder requesting or joining in a registration will, severally and not jointly, indemnify and hold harmless the Corporation, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Corporation within the meaning of the Securities Act, and any underwriter (within the meaning of the Securities Act) for the Corporation against any losses, claims, damages or liabilities to which the Corporation or any such director, officer, controlling person or underwriter may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto or (ii) the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information relating to and furnished to the Corporation by such Holder

 

8

 

expressly for use in connection with such registration; and will promptly reimburse the Corporation or any such director, officer, controlling person or underwriter for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this Section 10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld or delayed) and provided further that no Holder shall have any liability under this Section 10(b) in excess of the net proceeds actually received by such Holder in the relevant public offering.

 

(c)                                  Promptly after receipt by an indemnified party under this Section 10 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 10, notify the indemnifying party in writing of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties.  The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to his ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 10, but the omission so to notify the indemnifying party will not relieve him of any liability that he may have to any indemnified party otherwise than under this Section 10.

 

(d)                                 If the indemnification provided for in this Section 10 is required by its terms but is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party under Section 10(a) or Section 10(b) in respect of any losses, claims, damages, liabilities or expenses referred to herein, then each applicable indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of any losses, claims, damages, liabilities or expenses referred to herein in such proportion as is appropriate to reflect the relative fault of the Corporation and the selling Holders in connection with the statements or omissions described in such Section 10(a) or Section 10(b) which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations.  The relative fault of the Corporation and the selling Holders shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Corporation or the selling Holders and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.  The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in this Section 10, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim.  The provisions set forth in Section 10(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section 10(d); provided, however, that no additional notice shall be required with respect to any action for which notice has been given under subsection Section 10(c) for purposes of indemnification.  The Corporation and the selling Holders agree that it would not be just and equitable if contribution pursuant to this Section 10 were determined solely by pro rata allocation or by any other method of allocation which does not take account of the equitable

 

9

 

considerations referred to in this paragraph.  Notwithstanding the provisions of this Section 10(d), no Holder shall be required to contribute an amount in excess of the net proceeds actually received by such Holder in the relevant public offering.  No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

 

(e)                                  Notwithstanding the foregoing, to the extent that the provisions on indemnification contained in the underwriting agreements entered into among the Holders, the Corporation and the underwriters in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall be controlling as to the Registrable Shares included in the public offering.

 

SECTION 11.                     Registrations on Form S-3.

 

(a)                                 If (i) the Corporation shall receive a written request (specifying that it is being made pursuant to this Section 11) from one or more Holders that the Corporation file a registration statement on Form S-3 (or any successor form to Form S-3 regardless of its designation) for a public offering of Registrable Shares the reasonably anticipated aggregate price to the public of which would equal or exceed $1,000,000, and (ii) the Corporation is a registrant entitled to use Form S-3 (or any successor form to Form S-3) to register such shares, then the Corporation shall promptly notify all other Holders of such request and shall use its best efforts to cause all Registrable Shares that Holders have requested be registered to be registered on Form S-3 (or any successor form to Form S-3).

 

(b)                                 Notwithstanding the foregoing, (i) the Corporation shall not be obligated to effect a registration pursuant to this Section 11 during the period starting with the date sixty (60) days prior to the Corporation’s estimated date of filing of, and ending on a date six (6) months following the effective date of, a registration statement pertaining to an underwritten public offering of securities for the account of the Corporation; provided, that the Corporation is actively employing in good faith its best efforts to cause such registration statement to become effective and that the Corporation’s estimate of the date of filing such registration statement is made in good faith; (ii) the Corporation shall not be obligated to effect a registration pursuant to this Section 11 within six (6) months after the effective date of a prior registration under this Section 11; and (iii) if the Corporation shall furnish to the Holders a certificate signed by the President of the Corporation stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Corporation or its shareholders for a registration statement to be filed in the near future, then the Corporation’s obligation to use its best efforts to file a registration statement shall be deferred for a period not to exceed 90 days; provided, however, that the Corporation shall not be permitted to so defer its obligation more than once in any 12-month period.

 

(c)                                  The Holders’ rights to registration under this Section 11 are in addition to, and not in lieu of, their rights to registration under Section 2 and Section 3 of this Agreement.

 

SECTION 12.                     Limitation on Corporation Offerings.  The Corporation shall not register securities for sale for its own account (or, except as permitted by Section 14, any securities other

 

10

 

than Registrable Shares) in any registration requested pursuant to Section 2 or Section 11 unless permitted to do so by the written consent of the Holders of a majority of the Registrable Shares as to which registration has been requested unless the inclusion of securities for the account of the Corporation would not require a reduction in the number of Registrable Shares to be included in such registration, as determined by the managing underwriter.

 

SECTION 13.                     Reports Under Securities Exchange Act of 1934.  With a view to making available to the Holders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Corporation to the public without registration, the Corporation agrees to use its best efforts to:

 

(a)                                 make and keep public information available, as those terms are understood and defined in Rule 144, at all times subsequent to 90 days after the effective date of the first registration statement covering an underwritten public offering filed by the Corporation;

 

(b)                                 file with the SEC in a timely manner all reports and other documents, if any, required of the Corporation under the Securities Act and the 1934 Act and take such further action as the Holders may reasonably request, all to the extent required from time to time to enable the Holders to sell securities of the Corporation without registration; and

 

(c)                                  furnish to any Holder forthwith upon request a written statement by the Corporation that it has complied with the reporting requirements of Rule 144 (at any time after 90 days after the effective date of said first registration statement filed by the Corporation), and of the Securities Act and the 1934 Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Corporation, and such other reports and documents so filed by the Corporation as may be reasonably requested in availing any such holder to take advantage of any rule or regulation of the SEC permitting the selling of any such securities without registration.

 

SECTION 14.                     Limitations in Connection with Future Grants of Registration Rights.  Without the prior written consent of the Holders of at least two-thirds in voting power of then outstanding Registrable Shares held by Investors, the Corporation shall not grant rights to any person or entity:  (a) to cause the Corporation to register any of such person’s or entity’s securities of the Corporation; (b) to include such person’s or entity’s securities of the Corporation in any registration statement filed under Section 2 or Section 11 hereof; (c) to include such person’s or entity’s securities of the Corporation in any registration statement described in Section 3 hereof, unless, in the case of each of (a), (b) and (c), under the terms of such agreement, such person or entity may include such securities in any such registration only to the extent that the inclusion of his or its securities will not reduce the amount of Registrable Shares of the Holders which is included in such registration; or (d) otherwise to cause the registration of such person’s or entity’s securities of the Corporation in any manner which are superior to or pari passu with the registration rights granted herein to the Holders.

 

SECTION 15.                     Transfer of Registration Rights.  The registration rights and obligations of any Holder (and of any permitted transferee or assignee of any Holder or its permitted transferees or assignees) under this Agreement with respect to any Registrable Shares may be

 

11

 

transferred to any Affiliate of such Holder or such permitted transferee or assignee, or to any transferee who acquires (otherwise than in a registered public offering) at least five percent (5%) of the Registrable Shares then held by such Holder; provided, however, that (a) the Corporation shall be given written notice by the Holder at the time of any permitted transfer stating the name and address of the transferee or assignee and identifying the securities with respect to which the rights and obligations under this Agreement are being assigned and (b) the transferee or assignee shall execute an agreement to be bound by the terms of this agreement.  For purposes of this Section 15, an “Affiliate” of any Holder (or any transferee or assignee of any Holder) means any general or limited partner of any Holder (or transferee or assignee) that is a partnership, any member of any Holder that is an LLC or any person or entity that, directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with, such Holder or transferee or assignee.

 

SECTION 16.                     Stand-Off Agreement.  Each Holder, if requested by the Corporation and the managing underwriter of an offering by the Corporation of Common Stock pursuant to a registration statement under the Securities Act, shall agree not to sell publicly or otherwise transfer or dispose of any Registrable Shares or other securities of the Corporation held by such Holder for a specified period of time (not to exceed 180 days) immediately following the effective date of such registration statement; provided, that:

 

(a)                                 such agreement shall apply only to the initial public offering of the Corporation’s securities; and

 

(b)                                 all persons who hold shares of Common Stock, or securities convertible into or exchangeable or exercisable for shares of Common Stock, which in aggregate represent one percent (1%) or more of the shares of Common Stock then outstanding (which 1% shall include all securities convertible into or exchangeable or exercisable for shares of Common Stock, on an as converted, exchanged or exercised basis) (any such person, a “1% Stockholder”), and all officers and directors of the Corporation, enter into similar agreements.

 

Any discretionary waiver or termination of the restrictions of such agreements (including this Agreement) by the Corporation or the managing underwriter (other than discretionary waivers or releases up to an amount of $50,000 due to financial hardship) shall apply to all persons subject to such agreements on a pro rata basis, based upon the number of shares held by such persons.

 

SECTION 17.                     Future Events.  The Corporation will notify each Holder participating in a registration of the occurrence of any of the following events of which the Corporation is actually aware, and when so notified, each Holder will immediately discontinue any disposition of Registrable Shares until notified by the Corporation that such event is no longer applicable:

 

(a)                                 the issuance by the Commission or any state securities commission or agency of any stop order suspending the effectiveness of the registration statement or the initiation of any proceedings for that purpose (in which case the Corporation will make reasonable efforts to obtain the withdrawal of any such order or the cessation of any such proceedings); or

 

12

 

 

(b)                                 the existence of any fact which makes untrue any material statement made in the registration statement or prospectus or any document incorporated therein by reference or which requires the making of any changes in the registration statement or prospectus or any document incorporated therein by reference in order to make the statements therein not misleading (in which case the Corporation will make reasonable efforts to amend the applicable document to correct the deficiency).

 

SECTION 18.                     Notices.  All notices, requests, consents and other communications hereunder (“Notices”) to any party shall be contained in a written instrument addressed to such party at the address set forth below or such other address as may hereafter be designated in writing by the addressee to the addressor listing all parties and shall be deemed given (a) when delivered in person or duly sent by fax showing confirmation of receipt, (b) three days after being duly sent by first class mail postage prepaid (other than in the case of Notices to or from any non-U.S. resident, which Notices must be sent in the manner specified in clause (a) or (c)), or (c) two days after being duly sent by DHL, Federal Express or other recognized express international courier service:

 

(a)                                 if to the Corporation, to:

 

Acceleron Pharma Inc.

128 Sidney Street

Cambridge, MA 02139

 

with a copy to:

 

Ropes & Gray LLP

Prudential Tower

800 Boylston Street

Boston, MA 02199-3600

Attn: Marc Rubenstein

Fax: (617) 951-7050

 

(b)                                 if to the Investors, to their respective addresses set forth on Exhibit A of this Agreement.

 

SECTION 19.                     Miscellaneous.

 

(a)                                 This Agreement states the entire agreement of the parties concerning the subject matter hereof, and supersedes all prior agreements, written or oral, between or among them concerning such subject matter.

 

(b)                                 This Agreement may be amended, and compliance with any provision of this Agreement may be omitted or waived, only by the written agreement of the Corporation and the Holders of at least two-thirds in voting power of the then outstanding Registrable Shares; provided, however, that no rights of a Holder under this Agreement shall, without its consent, be adversely affected by any such amendment or waiver in any manner in which the rights of other Holders hereunder are not likewise adversely affected.

 

13

 

(c)                                  This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws.

 

(d)                                 This Agreement may be executed in any number of counterparts, each such counterpart shall be deemed to be an original instrument, and all such counterparts together shall constitute but one agreement.  Any such counterpart may contain one or more signature pages.  This Agreement may be executed by facsimile signature pages.

 

[Remainder of page intentionally left blank.]

 

14

 

IN WITNESS WHEREOF, the parties have executed this Amended and Restated Registration Rights Agreement as a contract under seal as of the date first written above.

 

 

	
 
    	
ACCELERON PHARMA INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
John   Knopf, Chief Executive Officer
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
 
    	
POLARIS   VENTURE PARTNERS IV, L.P.
    
	
 
    	
 
    
	
 
    	
BY:   POLARIS VENTURE MANAGEMENT CO. IV, L.L.C.
    
	
 
    	
ITS   GENERAL PARTNER
    
	
 
    	
 
    
	
 
    	
POLARIS   VENTURE PARTNERS ENTREPRENEURS’ FUND IV, L.P.
    
	
 
    	
 
    
	
 
    	
BY:   POLARIS VENTURE MANAGEMENT CO. IV L.L.C.
    
	
 
    	
ITS   GENERAL PARTNER
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
William   E. Bilodeau
    
	
 
    	
Attorney-in-fact
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
 
    	
VENROCK   PARTNERS, L.P.,
    
	
 
    	
 
    
	
 
    	
by   its General Partner, Venrock Partners Management, LLC
    
	
 
    	
 
    
	
 
    	
VENROCK   ASSOCIATES IV, L.P.,
    
	
 
    	
 
    
	
 
    	
by   its General Partner, Venrock Management IV, LLC
    
	
 
    	
 
    
	
 
    	
VENROCK   ENTREPRENEURS FUND IV, L.P.,
    
	
 
    	
 
    
	
 
    	
by   its General Partner, VEF Management IV, LLC
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
ADVANCED   TECHNOLOGY VENTURES VII, L.P.
    	
 
    	
ADVANCED   TECHNOLOGY VENTURES VII(C), L.P.
    
	
By:
    	
ATV   Associates VII, L.L.C.
    	
 
    	
By:
    	
ATV   Associates VII, L.L.C.
    
	
 
    	
Its   General Partner
    	
 
    	
 
    	
Its   General Partner
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
Name:
    	
Jean   George
    	
 
    	
Name:
    	
Jean   George
    
	
Title:
    	
Managing   Director
    	
 
    	
Title:
    	
Managing   Director
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
ADVANCED TECHNOLOGY VENTURES VI, L.P.
    	
 
    	
ATV   ALLIANCE 2003, L.P.
    
	
By:
    	
ATV   Associates VI, L.L.C.
    	
 
    	
By:
    	
ATV   Alliance Associates, L.L.C.
    
	
 
    	
Its   General Partner
    	
 
    	
 
    	
Its   General Partner
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
Name:
    	
Jean   George
    	
 
    	
Name:
    	
Jean   George
    
	
Title:
    	
Managing   Director
    	
 
    	
Title:
    	
Managing   Director
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
ADVANCED TECHNOLOGY VENTURES VII(B), L.P.
    	
 
    	
ATV   ENTREPRENEURS VI, L.P.
    
	
By:
    	
ATV   Associates VII, L.L.C.
    	
 
    	
By:
    	
ATV   Associates VI, L.L.C.
    
	
 
    	
Its   General Partner
    	
 
    	
 
    	
Its   General Partner
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
Name:
    	
Jean   George
    	
 
    	
Name:
    	
Jean   George
    
	
Title:
    	
Managing   Director
    	
 
    	
Title:
    	
Managing   Director
    
	
 
    	
 
    	
 
    	
 
    
	
ATV ENTREPRENEURS VII, L.P.
    	
 
    	
 
    
	
By:
    	
ATV   Associates VII, L.L.C.
    	
 
    	
 
    
	
 
    	
Its   General Partner
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
 
    
	
Name:
    	
Jean   George
    	
 
    	
 
    
	
Title:
    	
Managing   Director
    	
 
    	
 
    
							

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
 
    	
CELGENE   CORPORATION
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
Perry   Karsen
    
	
 
    	
Title:
    	
Chief   Operating Officer
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
ORBIMED PRIVATE INVESTMENTS II, LP
    	
 
    	
ORBIMED   PRIVATE INVESTMENTS II (QP), LP
    
	
By:
    	
Orbimed   Capital GP II LLC
    	
 
    	
By:
    	
Orbimed   Capital GP II LLC
    
	
 
    	
its   General Partner
    	
 
    	
 
    	
its   General Partner
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
Name:
    	
Carl   Gordon
    	
 
    	
Name:
    	
Carl   Gordon
    
	
Title:
    	
Member
    	
 
    	
Title:
    	
Member
    
	
 
    	
 
    	
 
    	
 
    
	
ORBIMED PRIVATE INVESTMENTS II, LP
    	
 
    	
 
    
	
By:
    	
Orbimed   Capital GP II LLC
    	
 
    	
 
    
	
 
    	
its   General Partner
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
 
    
	
Name:
    	
Carl   Gordon
    	
 
    	
 
    
	
Title:
    	
Member
    	
 
    	
 
    
							

 

Signature Page to Registration Rights Agreement

 

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
 
    	
APPLIED   GENOMIC TECHNOLOGY CAPITAL FUND, L.P.; AGTC ADVISORS FUND, L.P.
    
	
 
    	
 
    
	
 
    	
Each   by: AGTC Partners, L.P., its General Partner
    
	
 
    	
 
    
	
 
    	
By:   NewcoGen Group Inc., its General Partner
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
 
    	
BESSEMER   VENTURE PARTNERS VII L.P.,
    
	
 
    	
BESSEMER   VENTURE PARTNERS VII INSTITUTIONAL L.P.
    
	
 
    	
 
    
	
 
    	
By:   Deer VII & Co. L.P., their General Partner
    
	
 
    	
By:   Deer VII & Co. Ltd., its General Partner
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
J.   Edmund Colloton
    
	
 
    	
Title:
    	
Director
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
 
    	
ALKERMES, INC.
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
Michael   Landine
    
	
 
    	
Title:
    	
Senior   Vice President
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
SUTTER   HILL VENTURES, A CALIFORNIA LIMITED PARTNERSHIP
    	
 
    	
DAVID   L. ANDERSON, TRUSTEE OF THE ANDERSON LIVING TRUST U/A/D 1/22/98
    
	
By:
    	
Sutter   Hill Ventures, L.L.C.
    	
 
    	
By   Robert Yin Under Power of Attorney
    
	
 
    	
its   General Partner
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
 
    
	
By:
    	
 
    	
 
    	
David   L. Anderson, Trustee
    
	
Name:   Jeffrey W. Bird
    	
 
    	
 
    
	
Title:   Managing Director
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
ANVEST,   L.P.
    	
 
    	
G.   LEONARD BAKER, JR. AND MARY ANNE BAKER, CO-TRUSTEES OF THE BAKER REVOCABLE   TRUST U/A/D 2/3/03
    
	
By   Robert Yin Under Power of Attorney
    	
 
    
	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By   Robert Yin Under Power of Attorney
    
	
David   L. Anderson, Trustee of The Anderson Living 
    	
 
    	
 
    	
 
    
	
Trust   U/A/D 1/22/98, General Partner
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
G.   Leonard Baker, Jr., Trustee
    
	
 
    	
 
    	
 
    
	
SAUNDERS   HOLDINGS, L.P.
    	
 
    	
YOVEST,   L.P.
    
	
By   Robert Yin Under Power of Attorney
    	
 
    	
By   Robert Yin Under Power of Attorney
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
G.   Leonard Baker, Jr., Trustee of the Baker Revocable Trust U/A/D 2/3/03,   General Partner
    	
 
    	
William   H. Younger, Jr., Trustee of The William H. Younger, Jr. Revocable Trust U/A/D   8/5/09, General Partner
    
	
 
    	
 
    	
 
    
	
WILLIAM   H. YOUNGER, JR. TRUSTEE, THE WILLIAM H. YOUNGER, JR. REVOCABLE TRUST U/A/D   8/5/2009
   By Robert Yin Under Power of Attorney
    	
 
    	
DAVID   E. SWEET AND ROBIN T. SWEET, AS TRUSTEES OF THE DAVID AND ROBIN SWEET LIVING   TRUST, DATED 7/6/04
    
	
 
    	
 
    	
By   Robert Yin Under Power of Attorney
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
William   H. Younger, Jr., Trustee
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
ROOSTER   PARTNERS, LP

By   Robert Yin Under Power of Attorney
    	
 
    	
GREGORY   P. SANDS AND SARAH J.D. SANDS AS TRUSTEES OF GREGORY P. AND SARAH J.D. SANDS   TRUST AGREEMENT DATED 2/24/99
    
	
By:
    	
 
    	
 
    	
By   Robert Yin Under Power of Attorney
    
	
Tench   Coxe, Trustee of The Coxe Revocable Trust U/A/D 
    	
 
    	
 
    	
 
    
	
4/23/98,   General Partner
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Gregory   P. Sands, Trustee
    
							

 

Signature Page to Registration Rights Agreement

 

 

	
JAMES   C. GAITHER, TRUSTEE OF THE GAITHER REVOCABLE TRUST U/A/D 9/28/2000
    	
 
    	
TALLACK   PARTNERS, L.P.

By   Robert Yin Under Power of Attorney
    
	
By   Robert Yin Under Power of Attorney
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
By:
    	
 
    
	
By:
    	
 
    	
 
    	
James   C. Gaither, Trustee of The Gaither Revocable Trust U/A/D 9/28/2000, General   Partner
    
	
James   C. Gaither, Trustee
    	
 
    
	
 
    	
 
    	
 
    
	
 

By   Robert Yin Under Power of Attorney
    	
 
    	
RONALD   D. BERNAL AND PAMELA M. BERNAL AS TRUSTEES OF THE BERNAL FAMILY TRUST U/D/T   11/3/1995
    
	
By:
    	
 
    	
 
    	
By   Robert Yin Under Power of Attorney
    
	
James   C. Gaither
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    
	
JAMES   N. WHITE AND PATRICIA A. O’BRIEN AS TRUSTEES OF THE WHITE FAMILY TRUST U/A/D   4/3/97
    	
 
    	
JEFFREY   W. BIRD AND CHRISTINA R. BIRD AS TRUSTEES OF JEFFREY W. AND CHRISTINA R. BIRD   TRUST AGREEMENT DATED 10/31/00
    
	
By   Robert Yin Under Power of Attorney
    	
 
    	
By   Robert Yin Under Power of Attorney
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
James   N. White, Trustee
    	
 
    	
Jeffrey   W. Bird, Trustee
    
	
 
    	
 
    	
 
    
	
ANDREW   T. SHEEHAN AND NICOLE J. SHEEHAN AS TRUSTEES OF SHEEHAN 2003 TRUST

By   Robert Yin Under Power of Attorney
    	
 
    	
MICHAEL   L. SPEISER AND MARY ELIZABETH SPEISER, CO TRUSTEES OF SPEISER TRUST AGREEMENT   DATED 7/19/06
    
	
 
    	
 
    	
By   Robert Yin Under Power of Attorney
    
	
By:
    	
 
    	
 
    	
 
    	
 
    
	
Andrew   T. Sheehan, Trustee
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Michael   L. Speiser, Trustee
    
	
 
    	
 
    	
 
    
	
MICHAEL   L. NAAR AND DIANE J. NAAR AS TRUSTEES OF NAAR FAMILY TRUST U/A/D 12.22.94
   By Robert Yin Under Power of Attorney
    	
 
    	
PATRICK   ANDREW CHEN AND YU-YING CHIU CHEN AS TRUSTEES OF PATRICK AND YING CHEN 2001 LIVING   TRUST DATED 3/17/01
    
	
 
    	
 
    	
By   Robert Yin Under Power of Attorney
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    
	
TENCH   COXE AND SIMONE OTUS COXE, CO-TRUSTEES OF THE COXE REVOCABLE TRUST U/A/D   4/23/98
    	
 
    	
 
    
	
By   Robert Yin Under Power of Attorney
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
 
    
	
Tench   Coxe, Trustee
    	
 
    	
 
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Sheryl W. Casella
    	
 
    	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Sheryl W. Hossack
    
	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Gregory P. Sands
    	
 
    	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Tench Coxe
    
	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Ronald D. Bernal
    	
 
    	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Lynne M. Brown (Rollover)
    
	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David E. Sweet
    	
 
    	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO William H. Younger, Jr.
    
	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David E. Sweet (Rollover)
    	
 
    	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Robert Yin
    
	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Lynne B. Graw
    	
 
    	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David L. Anderson
    
	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Lynne B. Graw (Rollover)
    	
 
    	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Andrew T. Sheehan
    
	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Diane J. Narr
    	
 
    	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Yu-Ying Chen
    
	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Patricia Tom (Post)
    	
 
    	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Patricia Tom (Pre)
    
	
Wells   Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Patricia Tom (Rollover)
    	
 
    	
Wells   Fargo Bank, N.A. FBO James N. White Roth IRA
    
	
Wells   Fargo Bank, N.A. FBO Jeffrey W. Bird Roth IRA
    	
 
    	
Wells   Fargo Bank, N.A. FBO Gregory P. Sands Roth IRA
    
	
Wells   Fargo Bank, N.A. FBO David E. Sweet Roth IRA
    	
 
    	
 
    

 

 

	
By:
    	
 
    	
 
    	
 
    
	
Name:
    	
Thomas   M. Thurston
    	
 
    	
 
    
	
Title:
    	
Vice   President
    	
 
    	
 
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
QVT   FUND LP, 
    	
 
    	
QUINTESSENCE   FUND LP, 
    
	
 
    	
 
    	
 
    
	
BY:   ITS GENERAL PARTNER, QVT ASSOCIATES GP LLC
    	
 
    	
BY:   ITS GENERAL PARTNER, QVT ASSOCIATES GP LLC 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
Name:
    	
Keith   S. Manchester 
    	
 
    	
Name:
    	
Keith   S. Manchester 
    
	
Title:
    	
Portfolio   Manager
    	
 
    	
Title:
    	
Portfolio   Manager
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

	
AVALON   VENTURES VI, LP
    	
 
    	
AVALON   VENTURES VI, GP FUND, LLC
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
	
Name:
    	
Douglas   Downs
    	
 
    	
Name:
    	
Douglas   Downs
    
	
Title:
    	
Authorized   Signer & CFO
    	
 
    	
Title:
    	
Authorized   Signer & CFO
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
 
    	
MIDCAP   FINANCIAL, LLLC,
    
	
 
    	
a   Delaware limited liability company
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
Luis   Viera
    
	
 
    	
Title:
    	
Managing   Director
    

 

Signature Page to Registration Rights Agreement

 

 

ACCELERON PHARMA INC.

 

Amended and Restated Registration Rights Agreement

 

Investor Signature Page

 

By executing this page in the space provided, the undersigned hereby agrees (i) that it is an “Investor” as defined in the Amended and Restated Registration Rights Agreement dated as of the date first written above, by and among Acceleron Pharma Inc. and the parties named therein (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (iii) that it is bound by all terms and conditions of the Registration Rights Agreement.

 

EXECUTED as of the date first written above.

 

 

	
 
    	
HERCULES   TECHNOLOGY II, L.P.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
K.   Nicholas Martitsch
    
	
 
    	
Title:
    	
Associate   General Counsel
    

 

Signature Page to Registration Rights Agreement

 

 

 

Exhibit A

 

Investors

 

	
Investor
    	
 
    	
Address
    
	
Bessemer Venture Partners VII L.P.
    	
 
    	
c/o Bessemer Venture Partners

1865 Palmer Avenue, Suite 104

Larchmont, NY 10538
    
	
Bessemer Venture Partners VII Institutional L.P.
    	
 
    	
c/o Bessemer Venture Partners

1865 Palmer Avenue, Suite 104

Larchmont, NY 10538
    
	
Polaris Venture Partners IV, L.P.

 
    	
 
    	
1000 Winter Street, Suite 3350

Waltham, MA 02451
    
	
Polaris Venture Partners Entrepreneurs’ Fund IV, L.P.

 
    	
 
    	
1000 Winter Street, Suite 3350

Waltham, MA 02451
    
	
OrbiMed Private Investments II LP

 
    	
 
    	
OrbiMed Advisors, LLC

Attn: Carl Gordon
   767 Third Avenue
   30th Floor
   New York, NY  10017
    
	
OrbiMed Private Investments II (QP), LP
    	
 
    	
OrbiMed Advisors, LLC

Attn: Carl Gordon
   767 Third Avenue
   30th Floor
   New York, NY  10017
    
	
UBS Juniper Crossover Fund, LLC

 
    	
 
    	
OrbiMed Advisors, LLC

Attn: Carl Gordon
   767 Third Avenue
   30th Floor
   New York, NY  10017
    
	
Advanced Technology Ventures VII, LP
    	
 
    	
500 Boylston Street, Suite 1380

Boston, MA 02116
    
	
Advanced Technology Ventures VII (B), LP
    	
 
    	
500 Boylston Street, Suite 1380

Boston, MA 02116
    
	
Advanced Technology Ventures VII (C), LP
    	
 
    	
500 Boylston Street, Suite 1380

Boston, MA 02116
    
	
ATV Entrepreneurs VII, LP
    	
 
    	
500 Boylston Street, Suite 1380

Boston, MA 02116
    
	
Advanced Technology Ventures VI, LP
    	
 
    	
500 Boylston Street, Suite 1380

Boston, MA 02116
    
	
ATV Entrepreneurs VI, LP
    	
 
    	
500 Boylston Street, Suite 1380

Boston, MA 02116
    
	
Applied Genomic Technology Capital Fund, L.P.

 
    	
 
    	
One Memorial Drive, 7th Floor

Cambridge, MA 02142
    
	
AGTC Advisors Fund, L.P.
    	
 
    	
One Memorial Drive, 7th Floor

Cambridge, MA 02142
    
	
Venrock Partners, L.P.

 
    	
 
    	
530 Fifth Avenue, 22nd Floor

New York, NY 10036
    
	
Venrock Associates IV, L.P.

 
    	
 
    	
530 Fifth Avenue, 22nd Floor

New York, NY 10036
    
	
Venrock Entrepreneurs Fund IV, L.P.

 
    	
 
    	
530 Fifth Avenue, 22nd Floor

New York, NY 10036
    

 

 

	
Sutter Hill Ventures, A California Limited Partnership
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
David L. Anderson, Trustee of The Anderson Living Trust U/A/D 1/22/98
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Anvest, L.P.
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
G. Leonard Baker, Jr. and Mary Anne Baker, Co-Trustees of The   Baker Revocable Trust U/A/D 2/3/03
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Saunders Holdings, L.P.
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Yovest, L.P.
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Rooster Partners, LP
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Gregory P. Sands and Sarah J.D. Sands as Trustees of Gregory P. and   Sarah J.D. Sands Trust Agreement Dated 2/24/99
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
James C. Gaither, Trustee of The Gaither Revocable Trust U/A/D   9/28/2000
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Tallack Partners, L.P.
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
James N. White and Patricia A. O’Brien as Trustees of The White   Family Trust U/A/D 4/3/97
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Jeffrey W. Bird and Christina R. Bird as Trustees of Jeffrey W. and   Christina R. Bird Trust Agreement Dated 10/31/00
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Ronald D. Bernal and Pamela M. Bernal as Trustees of The Bernal   Family Trust U/D/T 11/3/1995
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Andrew T. Sheehan and Nicole J. Sheehan as Trustees of Sheehan 2003   Trust
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Michael I. Naar and Diane J. Naar as Trustees of Naar Family Trust   U/A/D 12.22.94
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Patrick Andrew Chen and Yu-Ying Chiu Chen as Trustees of Patrick and   Ying Chen 2001 Living Trust Dated 3/17/01
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Sherryl W.   Casella
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    

 

 

	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Tench Coxe

 
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David L.   Anderson
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO William H.   Younger, Jr.
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Andrew T.   Sheehan
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David E. Sweet   (Rollover)
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Lynne B. Graw
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Diane J. Naar
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Yu-Ying Chen
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Patricia Tom   (Post)
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Robert Yin
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Lynne B. Graw   (Rollover)
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Lynne B. Graw
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Patricia Tom   (Rollover)
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    

 

 

	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Ronald D.   Bernal
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David E. Sweet
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Sherryl W.   Hossack
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Lynne M. Brown   (Rollover)
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Patricia Tom   (Pre)
    	
 
    	
Attention: Vicki Bandel

600 California Street, 12th Floor

MAC A0193-120

San Francisco, CA  94108
    
	
MPM BioEquities Master Fund LP
    	
 
    	
The John Hancock Tower

200 Clarendon Street, 54th floor

Boston, MA 02116
    
	
QVT Fund LP
    	
 
    	
c/o QVT Financial LP

1177 Avenue of the Americas

9th Floor

New York, NY 10036
    
	
Quintessence Fund L.P.
    	
 
    	
c/o QVT Financial LP

1177 Avenue of the Americas

9th Floor

New York, NY 10036
    
	
Hercules Technology II, L.P.

 
    	
 
    	
400 Hamilton Ave, Suite 310

Palo Alto, CA 94301
    
	
Avalon Ventures VI, LP
    	
 
    	
1134 Kline St

La Jolla, CA. 92037
    
	
Avalon Ventures VI, GP Fund, LLC
    	
 
    	
1134 Kline St

La Jolla, CA. 92037
    
	
Wylie Vale

 
    	
 
    	
1643 Valdes Drive

La Jolla, CA 92037
    
	
Tom Maniatis
    	
 
    	
2828 Broadway

Apartment 7E

New York, NY 10025
    
	
Peter Crisp

 
    	
 
    	
103 Horseshoe Rd.

Mill Neck, NY 11765-1005
    
	
Mark Ptashne
    	
 
    	
9 East 79th St.

New York, NY 10075
    
	
David Shaw

 
    	
 
    	
542 Black Point Rd..

Scarborough, ME 04074
    
	
David Molowa
    	
 
    	
1030 Wychwood Road

Westfield, NJ 07090
    
	
The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable   Trust Dated January 18, 2005
    	
 
    	
1647 Ralston Ave

Belmont, CA 94002
    

 

 

	
Paul Walker
    	
 
    	
15 Cervantes Blvd, #306

San Francisco, CA 94123
    
	
Vaughn Kailian
    	
 
    	
1100 Fitzpatrick Lane, PO Box 70

Bodega, CA 94922
    
	
Leon Smith
    	
 
    	
39 Holton Lane

Essex Fells, NJ 07021
    
	
Michael Kassen 2003 GRAT
    	
 
    	
c/o Michael M. Kassen

315 North Avenue

Westport, CT 06880
    
	
Next Chapter Holdings LP
    	
 
    	
c/o Mark R. Pattis

600 Central Avenue, Suite 205-210

Highland Park, IL 80035
    
	
Ropart Investments LLC
    	
 
    	
Attn: Peter Cawley

One East Weaver Street

Greenwich, CT 06831
    
	
UM Multi-Strategy Fund
    	
 
    	
c/o Cadogen Management LLC

Attn: Kyle Pickens

149 Fifth Avenue, 15th Floor

New York, NY 10010
    
	
Victor Dzau
    	
 
    	
4006 Dover Road

Durham, NC 27707
    
	
Valinco Investments Limited
    	
 
    	
c/o Denlow Private Trustco Limited

29 Middle Road

Devonshire DV 06

Bermuda
    
	
DGAM Alternative Strategy Fund LP
    	
 
    	
Desjardins Global Asset Management

Attn: Florent Salmon

1 Complexe Desjardins, South Tower, 25th   Floor

Montreal, QC H5B 1B3

Canada
    
	
DGAM Alternative Strategy Fund II SPC CELL A
    	
 
    	
Desjardins Global Asset Management

Attn: Florent Salmon

1 Complexe Desjardins, South Tower, 25th   Floor

Montreal, QC H5B 1B3

Canada
    
	
Citco Global Custody (NA) N.V. as custodian for Absolutissimo-Cadogan
    	
 
    	
Attn:   Chantel Winkel

Schottegatweg   Oost 44

Curacao

Netherlands   Antilles
    
	
Alkermes, Inc.
    	
 
    	
852 Winter Street

Waltham, MA 02451
    
	
Celgene Corporation
    	
 
    	
86 Morris Avenue

Summit, NJ    07901
    
	
MidCap Financial, LLC
    	
 
    	
7735 Old Georgetown Road

Suite 400

Bethesda, MD 20814

Attn: Bob Goodridge
    
	
Wells Fargo Bank N.A. FBO James N. White Roth IRA
    	
 
    	
Wells Fargo Trust Operations - CHOPS

NW 7595

Account # 23883800

P.O. Box 1450

Minneapolis, MN 55485-759
    

 

 

	
Wells Fargo Bank N.A. FBO Jeffrey W. Bird Roth IRA
    	
 
    	
Wells Fargo Trust Operations - CHOPS

NW 7595

Account # 23883700

P.O. Box 1450

Minneapolis, MN 55485-759
    
	
Tench Coxe and Simone Otus Coxe, Co-Trustees of The Coxe Revocable   Trust U/A/D 4/23/98
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA  94304-1005
    
	
William H. Younger, Jr., Trustee, The Younger Living Trust,   U/A/D 1/20/95
    	
 
    	
c/o Sutter Hill Ventures

755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
William H. Younger, Jr. Trustee, The William H. Younger, Jr.,   Revocable Trust U/A/D 8/5/2009
    	
 
    	
c/o Sutter Hill Ventures

755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Michael L. Speiser and Mary Elisabeth Speiser, Co-Trustees of Speiser   Trust Agreement Dated 7/19/06
    	
 
    	
755 Page Mill Road, Suite A-200

Palo Alto, CA  94304-1005
    
	
David E. Sweet and Robin T. Sweet, as Trustees of the David and Robin   Sweet Living Trust, dated 7/6/04
    	
 
    	
c/o Sutter Hill Ventures

755 Page Mill Road, Suite A-200

Palo Alto, CA 94304-1005
    
	
Wells Fargo Bank N.A. FBO Gregory P. Sands Roth IRA
    	
 
    	
Wells Fargo Trust Operations - CHOPS

NW 7595

Account # 23883300

P.O. Box 1450

Minneapolis, MN 55485-759
    
	
Wells Fargo Bank N.A. FBO David E. Sweet Roth IRA
    	
 
    	
Wells Fargo Trust Operations - CHOPS

NW 7595

Account # 23883400

P.O. Box 1450

Minneapolis, MN 55485-7595

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]